srk-015
mAbexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Apr 22, 2019 (NCT03921528)
Timeline
Indications
Mechanism of action
- Growth/differentiation factor 8INHIBITOR
Growth/differentiation factor 8 inhibitor
Targets latent myostatin (promyostatin).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594326 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07047144 | Phase 2 | Sep 15, 2025 | Scholar Rock, Inc. |
| NCT06445075 | Phase 2 | May 21, 2024 | Scholar Rock, Inc. |
| NCT05626855 | Phase 3 | Apr 24, 2023 | Scholar Rock, Inc. |
| NCT05156320 | Phase 3 | Feb 28, 2022 | Scholar Rock, Inc. |
| NCT03921528 | Phase 2 | Apr 22, 2019 | Johns Hopkins University, Scholar Rock, Inc. |
| NCT06877689 | N/A | — | Scholar Rock, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Scholar Rock, Inc. | For profit | 6 | 6 | 3 | 2019 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1